CRADD Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the CRADD (RAIDD) gene is disrupted in Raji B lymphocytes. Generated without clonal selection, this heterogeneous pool provides a loss-of-function model that retains natural cell-to-cell variation, suitable for studying CRADD-dependent signaling without artifacts of monoclonal selection.
Raji cells, derived from an EBV-transformed Burkitt??s lymphoma, maintain B-cell characteristics such as immunoglobulin secretion and antigen presentation. Their robust growth, high transfectability, and relevance to B-cell malignancies make them an ideal host for gene knockout studies focused on lymphoma biology and apoptosis.
CRADD/RAIDD serves as the adaptor linking PIDD1 to caspase-2 in the PIDDosome complex, a key mediator of DNA damage-induced apoptosis. Upon p53-dependent PIDD1 upregulation, CRADD recruits caspase-2, leading to its activation, Bid cleavage, cytochrome c release, and commitment to intrinsic apoptosis. Thus, CRADD operates downstream of p53 and PIDD1 and upstream of caspase-2, Bax, and mitochondrial events, acting as a tumor-suppressive checkpoint.
In Raji cells, CRADD knockout eliminates PIDDosome-driven apoptosis, conferring resistance to genotoxic agents. This model is particularly valuable for dissecting apoptosis evasion mechanisms in B-cell lymphomas, exploring drug resistance pathways, and evaluating therapeutic strategies that can reactivate cell death independently of CRADD. It also offers a system to investigate how EBV latency intersects with host apoptotic machinery.
The CRADD Knockout Raji Polyclonal Cells are well-suited for apoptosis and DNA damage response investigations using techniques such as Western blotting for caspase-2 cleavage products, Annexin V/propidium iodide staining for cell death quantification, ??-H2AX immunofluorescence to detect DNA breaks, and caspase activity assays. Co-immunoprecipitation experiments can probe remaining PIDDosome interactions, while RT-qPCR and flow cytometry enable expression profiling and cell cycle analysis. The polyclonal format facilitates pooled CRISPR screening and drug sensitivity studies. For further technical inquiries, please contact Ascent Research.
